Clinical Trial: Acetyl-L-Carnitine in the Treatment of Septic Shock
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock
Brief Summary: This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
Detailed Summary: This is a cross-over study which infuses ALC for 12 out of 18 hours (and placebo the other 6). Patients must have vasopressor-dependent septic shock and be free from renal failure, hepatic failure, and seizures to be eligible.
Sponsor: Vanderbilt University
Current Primary Outcome:
- Mean Arterial Blood Pressure [ Time Frame: 18 hours ]Mean Arterial blood pressure measured non-invasively at 18 hours
- Vasopressor Dose [ Time Frame: 6-24 hours ]
Original Primary Outcome:
- Mean Arterial Blood Pressure [ Time Frame: 24-36 hours ]
- Vasopressor Dose [ Time Frame: 6-24 hours ]
Current Secondary Outcome: Serum Lactate [ Time Frame: 12-36 hours ]
Original Secondary Outcome: Same as current
Information By: Vanderbilt University
Dates:
Date Received: January 2, 2008
Date Started: August 2006
Date Completion:
Last Updated: January 16, 2014
Last Verified: January 2014